Minute Insight: CMS Expands Medicare Coverage For CGM
Executive Summary
The new policy expands coverage to more Medicare beneficiaries using insulin to treat diabetes, as well as people who need help managing hypoglycemia, and removes the prior requirement of multiple daily insulin injections.
You may also be interested in...
Dexcom COO On Stelo CGM Plans, Apple Watch Developments, And Why Non-Invasive Glucose Monitoring Still Leaves Much To Desire
Exec Chat: Dexcom’s COO Jake Leach joined a panel discussion on the future of biosensing at CES 2024, where biowearables and glucose tech ranked among hot topics. He also spoke to Medtech Insight about plans for the company’s new CGM called Stelo, designed for people with type 2 diabetes who do not use insulin, Dexcom’s work with Apple to enable CGM users, and non-invasive monitoring prospects.
Dexcom Tries To Close Gap On Abbott in CGM
The continuous glucose monitoring space is expanding fast enough to accommodate two big players. Both Dexcom and Abbott recorded double-digit sales growth during the last quarter.
Exec Chat: Dexcom’s CEO On Meeting New CGM Markets While Scoping Consumer Opportunities
In this first of a series of Exec Chats with leaders at major diabetes companies presenting at ADA’s Scientific Sessions 2023, CEO Kevin Sayer discusses Dexcom’s ambitious R&D map to expand into metabolic health and develop innovative new products for diabetes and consumer markets.